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C ardiovascular diseases are the leading cause of death worldwide. 1, 2 Atherosclerosis, the underlying cause of most of these diseases, is considered as a chronic inflammatory disorder of the vascular wall, characterized by the accumulation of lipids, inflammatory cell infiltration, cell death, and fibrosis. 3 The initial phase of atherosclerosis is considered a maladaptive inflammatory response to the retention of low-density lipoproteins (LDLs) in the arterial intima. LDLs, trapped in the subendothelial space, undergo oxidative and enzymatic modifications and are internalized by macrophages, leading to the accumulation of intracellular cholesterol and foam cell formation, the prototypical cells of atherosclerosis. 4 Subendothelial LDL retention is mediated through their interaction with extracellular matrix proteoglycans (PGs). 5, 6 The most likely retention process involves the interaction of positively charged domains of apolipoprotein B (apoB) with negatively charged sulfate groups present in glycosaminoglycan (GAG) side chains of PGs. 7, 8 Therapeutic approaches for the treatment of atherosclerosis have been largely limited to the control of risk factors, such as hypercholesterolemia, hypertension, and diabetes mellitus. 9 The development of therapies targeting the interaction between lipoproteins and components of the extracellular matrix for the treatment of atherosclerosis has been poorly addressed. Along this line, endostatin, a fragment of collagen type XVIII released by proteolysis, was shown to interfere with lipoprotein retention in the subendothelial matrix. 10 In addition, immunization with apoB100-derived peptides containing one of the PG-binding sites has been considered as a promising strategy to block LDL retention in vivo. 11 Also, imatinib, a platelet-derived growth factor receptor inhibitor, has been demonstrated to inhibit GAG synthesis on vascular PGs and to reduce LDL binding in vitro and in vivo. 12 A new alternative immunization approach may use antibodies that recognize PGs and also have the ability to induce anti-anti-idiotype antibodies with similar recognition properties. In fact, anti-idiotypic monoclonal antibodies (mAbs) have been used successfully in cancer therapeutics to overcome the poor immunogenicity of some tumorassociated antigens. [13] [14] [15] [16] P3 is a murine mAb that recognizes N-glycolyl-(NeuGc)-containing gangliosides and sulfated glycolipids. 17, 18 This mAb elicited a strong anti-idiotypic antibody (Ab2) response, even in the absence of adjuvants or carrier proteins. 19 P3 mAb has an arginine motif at the heavy chain complementary determining region 3, which can be represented as R98-X-X-R100a (where numbers are according to Kabat system and X is any residue). 20 This segment is crucial for the binding of murine P3 mAb to gangliosides, 21, 22 and it is also found in the principal PG-binding sequence (site B) in the apoB moiety of LDL. 23 Chimeric mouse/human variant of P3 mAb that retain its properties was generated, 24 and its mutants E99→R (chP3R99) and R98→S (chP3S98) present the same reactivity against 1E10 Ab2 mAb but a higher and lower reactivity, respectively, against their antigens compared with the wild chimeric P3 antibody. 24, 25 In our previous work, we characterized chP3R99 mAb properties to bind sulfated GAGs and inhibit LDL-chondroitin sulfate (CS) association, in addition to abrogating LDL oxidation in vitro. 26 Furthermore, rabbits immunized with chP3R99 showed reduced aortic arch lesions and lower macrophage infiltration after short-term treatment with Lipofundin. The atheroprotective effect was associated with the induction of anti-CS antibodies in chP3R99immunized rabbits. 26 The present study aimed to investigate the potential of active immunization with chP3R99, along with the induction of an idiotype/anti-idiotype network, to prevent atherosclerotic lesion development in apoE-deficient (apoE −/− ) mice fed with a high-fat, high-cholesterol diet, a model that features the progressive series of atherogenic events seen in humans with increased leukocyte and endothelium adhesion events, monocyte-derived macrophage foam cell formation, and late development of more advanced fibrous lesions. 27 However, apoE gene deletion is associated with the accumulation of verylow-density lipoproteins (VLDLs) and chylomicron remnants containing apoB48 rather than apoB100, thereby interacting with PGs via an alternate positively charged region. 28 In this scenario, anti-idiotypic antibodies generated against the idiotype of chP3R99 mAb could mimic the original antigen and elicit the induction of Ab3 antibodies with properties similar to chP3R99 (Ab1). These anti-anti-idiotypic antibodies (Ab3, Ab5) may block apoB-containing lipoproteins binding to sulfated PGs, preventing their retention in the arterial intima and thus, their modification and uptake by macrophages.
Materials and Methods
To assess the antiatherogenic effect of chP3R99 mAb immunization, 4-week-old male apoE −/− mice were fed with a high-fat, high-cholesterol diet containing 40% wt/wt fat and 1.25% wt/wt cholesterol (D12108; Research Diet Inc) and treated from 6 weeks of age with subcutaneous injections of 50 μg of mAb at weekly or biweekly intervals. Serum was obtained before and during the immunization protocol. Mice were euthanized at 18 weeks of age, and whole aortas were isolated for morphometric analysis. In some experiments, the effect of the immunization was assessed by optical imaging using chP3R99 coupled to fluorescein isothiocyanate isomer I with the Optix MX3 scanner (ART). Immunohistochemical studies were performed for the detection of macrophages in mouse brachiocephalic arteries. Serum lipids were measured using commercially available reagents or kits. Induction of anti-idiotype, anti-anti-idiotype, and anti-GAG antibodies by chP3R99 mAb immunization was evaluated in mice sera or purified IgG fractions by ELISA. Inhibition of LDL oxidation in vitro by chP3R99 mAb and mice sera from immunized mice (IM) was analyzed by monitoring malondialdehyde (MDA) formation. The capacity of IM antibodies to block LDL retention and oxidation in the artery wall of apoE −/− mice fed with chow diet was evaluated by immunohistochemical studies. In vitro immunofluorescence studies were performed to evaluate the ability of chP3R99 mAb and IM antibodies to interfere with lipoprotein lipase/sphingomyelinase-dependent binding of LDL to atherosclerotic aortas. Inhibition of VLDL binding to human liver cells was evaluated by flow cytometry. A full description of the methods is given in the online-only Data Supplement.
Results

Active Immunization With chP3R99 Antibody Reduced Atherosclerotic Lesion Development
Oil Red-O-stained lesions from entire longitudinal aortas of PBS-and chP3S98-treated mice were distributed mainly to the aortic arch, iliac arteries, and abdominal aortas of high-fat, high-cholesterol-treated apoE −/− mice ( Figure 1A ). Mean aortic lesion areas of chP3R99-treated mice were reduced by 43% (P<0.01) and 40% (P<0.05) after biweekly and weekly administration compared with their respective PBS-treated groups ( Figure 1A and 1B) . In contrast, no difference was observed between chP3S98-and PBS-treated groups in either dosing regimen ( Figure 1A and 1B ). Yet, active immunization with antibodies did not modulate plasma lipid profiles ( Figure 1C To measure the kinetics of the response against both immunizing antibodies, sera from immunized mice (IM, diluted 1:200) were added to ELISA plates coated with 10 μg/mL of chP3R99 (A) or chP3S98 (B) monoclonal antibodies (mAbs), and the reaction was developed with peroxidase-conjugated goat anti-mouse IgG. Injections were given at 6, 7, 8, 9, 13 , and 17 weeks of age. Sera were obtained before starting immunizations and at 10, 14, and 18 weeks of age. Bars indicate media values. The immunodominance of chP3R99 and chP3S98 idiotypes in the antibody responses was measured by preincubating hyperimmune sera (diluted 1:400) from mice immunized with chP3R99 (C) or chP3S98 (D) with the isotype-matched irrelevant antibody hR3, and the remnant reactivity to chP3R99 and chP3S98 antibodies was assessed by ELISA. hR3 mAb-coated plates were used to measure the anti-isotype response in nonpreabsorbed sera and the absorption efficiency in preabsorbed sera. The levels are expressed as optical density (OD) values. Results are mean±SEM. **P<0.01 compared with preimmune (week 6) sera (A and B) and ***P<0.001 when the levels of anti-idiotype response and anti-isotype response were compared (C and D).
Immunization Induced a Specific Anti-Idiotype Antibody Response
Serological IgG reactivity against chP3R99 whole antibody molecule was detected in hyperimmune sera, reaching a plateau after mice received 4 doses of the chimeric mAb (Figure 2A ). In a similar manner, immunization with chP3S98 elicited a significant IgG serological antibody response compared with preimmune sera; however, higher levels of reactivity were not reached before the animals received 6 doses of the chimeric mAb ( Figure 2B ). To demonstrate that a specific response against the idiotypes of chP3R99 and chP3S98 antibodies was generated by immunization, hyperimmune mice sera were preabsorbed with hR3, an anti-human epidermal growth factor receptor mAb, used as the isotype-matched control mAb to block the anti-isotype response. The remaining reactivities to chP3R99 and chP3S98 mAbs (anti-idiotype responses) were measured by ELISA. As shown in Figure 2C and 2D, remnant reactivity to chP3R99 and chP3S98 mAbs was detected in mice sera after preabsorption with the isotypematched control mAb. The level of the anti-idiotype response against chP3R99 and chP3S98 mAbs was significantly higher than the anti-isotype response determined as the reactivity of nonpreabsorbed sera against hR3 mAb (P<0.001).
chP3R99 Immunization Induced an Antibody Response Against GAGs
Because chP3R99 is an Ab1 mAb, the induction of antianti-idiotype antibodies (Ab3) against GAG would depend on the capacity of this Ab1 mAb to activate an idiotype cascade. To probe this capacity of chP3R99, we studied the presence of anti-GAG antibodies in the sera of IM. The induction of anti-GAG antibodies in preimmunization and postimmunization sera samples from apoE −/− mice was tested by ELISA for binding to heparin-, dermatan sulfate-, and CS-coated plates. IgG anti-GAG response increased in a dose-dependent manner in chP3R99-hyperimmune versus preimmune sera reactivity (P<0.01; Figure 3A , 3C, and 3E), in contrast to the low reactivity of hyperimmune sera from chP3S98-IM ( Figure  3B , 3D, and 3F). Median titers of chP3R99-IM anti-heparin and anti-chP3R99 IgG antibodies were 1:6400 and 1:25 600, respectively. In addition, no reactivity was detected against oxidized LDL or proteins containing positively charged amino acid motifs, including fibronectin, 30 laminin, 31 collagen I, 32 and LDL 23 in the sera from chP3R99-IM ( Figure IV in the online-only Data Supplement). To further confirm the induction of an anti-idiotype cascade, we asked whether a fraction of the Ab3 response would bind one of the known chP3R99 Ab2 mAb, ch1E10. Results from ELISA showed the presence of Ab3 IgG in chP3R99-IM sera, which specifically reacted with the Ab2 mAb. No reactivity toward ch1E10 was detected using purified IgG from non-IM ( Figure 4A ). Furthermore, preincubation of IgG purified from chP3R99-IM with ch1E10 A, The reactivity of chP3R99-immunized mice (IM) IgG with ch1E10 Ab2 monoclonal antibody (mAb) was measured after the absorption of anti-isotypic antibodies with the isotype-matched control antibody hR3, and the remnant reactivity to ch1E10 mAb was assessed by ELISA. IgGs purified from non-IM were used as negative controls. hR3 mAb-coated plates were used to verify the absorption efficiency. The levels are expressed as optical density (OD) values. Results are mean±SEM. B, Inhibition of binding of chP3R99-IM IgG to chondroitin sulfate (CS) by ch1E10 Ab2 mAb was measured by incubating chP3R99-IM IgG or non-IM IgG (100 µg/mL) with ch1E10 mAb (500 µg/mL), and the remnant reactivity to CS was assessed by ELISA. Percentages of inhibition of Ab3 binding to CS were calculated relative to OD values obtained in wells where IgG antibodies from chP3R99-IM were added without preincubation with 1E10 mAb.
inhibited the binding of these antibodies to CS by 40% ( Figure 4B ).
Antibodies Induced by chP3R99 Immunization Inhibited LDL Retention and Oxidation
To assess the ability of the antibodies induced by chP3R99 immunization to prevent LDL-enhanced susceptibility to Cu 2+ oxidation induced by CS association, 33 we performed an MDA formation inhibition assay in vitro. In the presence of CS, LDL-increased oxidation was completely abrogated by chP3R99 and reduced by 70% with sera from chP3R99-IM ( Figure 5A ). In contrast, no inhibition of MDA formation was detected when hR3 mAb or hR3-IM sera were used ( Figure 5A ). In agreement, we showed reduced retention and oxidation of the lipoproteins in the artery wall of mice pretreated with a single intravenous dose of purified IgG from chP3R99-IM compared with that of mice that received either PBS or IgG from non-IM ( Figure 5B-5D ). The capacity of chP3R99 mAb and IgG purified from IM to inhibit the binding of LDL to aortas in the presence of lipoprotein lipase and sphingomyelinase, 34, 35 which have been shown to promote LDL retention in later stages of atherosclerosis development, has been assessed ex vivo. The results of this experiment showed that whereas anti-CS mAb inhibited LDL binding to aorta cross-sections by 51%, no inhibition was observed when chP3R99 mAbs or purified IgGs from IM were used as competitors ( Figure V in the online-only Data Supplement).
Antibodies Induced by chP3R99 Immunization Did Not Inhibit Binding of VLDLs to Hepatocytes
To determine whether chP3R99 or the antibodies in the sera from IM interfere with VLDL binding to heparan sulfate PGs on hepatocytes, we examined the effect of chimeric mAb, sera from IM, or purified IgG antibodies on biotinylated VLDL binding to Huh7 hepatoma cells. Whereas VLDL inhibited biotinylated VLDL binding by 71%, no inhibitory effect was Figure 5 . Effect of sera from mice immunized with chP3R99 on low-density lipoprotein (LDL) retention and oxidation. A, LDL oxidation was measured as nmol/L of malondialdehyde (MDA) produced by preincubating chondroitin sulfate (CS; 100 µg/mL) with sera from chP3R99-or hR3-immunized mice (IM, 1:50 dilution) or with chP3R99 or hR3 monoclonal antibodies (mAbs; 1 mg/mL), followed by the addition of LDL (25 µg/mL) and CuSO 4 (10 μmol/L) for 6 hours. MDA formation dependent on LDL-CS association was calculated after subtracting the absorbance values obtained in the absence of CS. The results are expressed as percentage inhibition of LDL oxidation relative to MDA values obtained in either PBS or sera from non-IM in the same conditions. B, Immunohistochemical staining of aortic arch sections showing LDL and oxidized LDL (oxLDL) using CBLDL3 and EO6 primary mAbs (10 μg/mL), respectively. Apolipoprotein E-deficient mice were injected intravenously with 50 μg of chP3R99-IM IgG or non-IM IgG 1 hour before LDL (4 mg/kg IV), and mice were euthanized 24 hours later (magnification, ×20). Scale bars, 50 μm. C and D, Percentages of CBLDL3 + and EO6 + areas with respect to total area, respectively. Data are mean±SEM of 3 mice per group. December 2012 observed when chP3R99 mAb, sera, or IgG antibodies from immunized animals were used as competitors ( Figure VI in the online-only Data Supplement).
Discussion
The current study shows that immunization with the mAb chP3R99, a mutant of the P3 mAb that strongly recognizes sulfatides 25 and GAG, 26 is atheroprotective in apoE −/− mice fed a high-fat, high-cholesterol diet. In agreement, the administration of 5 to 6 doses of chP3R99 mAb at biweekly or weekly intervals from 6 weeks of age prevented lesion formation by ≈40% in IM. In contrast, immunization of apoE −/− mice with chP3S98 mAb, a mutant with very low reactivity against GAGs, 26 did not show a significant reduction in aortic lesion formation. Neither total and high-density lipoprotein cholesterol nor triglyceride levels in serum were modified by treatment with the chimeric mAbs, indicating that the antiatherosclerotic properties associated with chP3R99 immunization involve mechanisms not related to lipid profile modulation in apoE −/− mice.
Although active immunization against several antigens, including oxidized epitopes such as MDA-LDL, MDA-apoB, or the phosphocholine epitope, was reported to induce significant reduction in atherosclerotic lesion size in different atherosclerosis-prone animal models, 36 to our knowledge this report is the first to show an atheroprotective effect after immunization with an antibody against GAGs associated with the generation of anti-anti-idiotype antibodies in apoE −/− mice. chP3R99 and chP3S98 mAbs were generated by substitution of a unique amino acid residue in the segment R98-X-X-R100a located in the heavy chain complementary determining region 3 of the chP3 antibody. 24, 25 Although both chimeric P3 idiotype variants differ in only 1 amino acid residue with respect to the original idiotype sequence, the substitutions increased the number of positively charged amino acids in the heavy chain complementary determining region 3 of chP3R99 while reducing that of chP3S98. Both antibodies elicited strong IgG responses against the whole chimeric antibody molecule used as immunogen. Furthermore, the antibody responses were predominantly against their idiotypes (antiidiotype response), as shown by elevated remnant reactivity after isotypic component absorption with an irrelevant IgG1. The remaining anti-idiotype or Ab2 response was significantly higher than the response detected in nonabsorbed sera against the isotype-matched control mAb (anti-isotype response), supporting the immunodominance of the determinants in the variable regions of the chimeric antibodies, despite the fact that 70% of the chimeric molecules are xenogenic with respect to the animal model. A similar result was obtained when BALB/c mice were immunized with chP3 antibody, 21 suggesting that the R99 and S98 mutations did not modify the immunogenic properties of the P3 idiotype. Although chP3R99 and chP3S98 mutants were capable of generating strong and dominant anti-idiotype antibody responses in apoE −/− mice, they differ in their capacity to generate antibody response against GAGs. In contrast to chP3S98, chP3R99 elicited a strong antibody response against the different sulfated GAGs tested. This immune response could be explained through the generation of an anti-idiotypic cascade in which a fraction of Ab2 induced by chP3R99 (Ab1) immunization behaves as a functional mimicry of GAG antigenic determinants, resulting in the generation of an anti-anti-idiotypic (Ab3) antibody response with the same specificity as Ab1. Rodriguez et al 37 reported the induction of NeuGc-containing gangliosides Ab3specific antibodies in murine P3 mAb-immunized chickens, a xenogenic model in which NeuGc-containing gangliosides are nonself antigens and the P3 idiotype was immunodominant. A similar finding was reported in non-small cell lung cancer patients immunized with the IE10 mAb, an anti-idiotype (Ab2) of the P3 mAb that mimics NeuGc-containing gangliosides. 38 Recently, we reported that the immunization of New Zealand White rabbits with chP3R99 mAb, before the acute induction of atherosclerosis by the intravenous infusion of a lipid emulsion, reduced or prevented atherosclerotic lesion formation. 26 This atheroprotective effect was mainly associated with the induction of anti-CS antibodies in immunized rabbits, which inhibited LDL-CS association and LDL oxidation in vitro rather than through a direct inhibition of the binding of LDL to PGs by chP3R99 mAb. 26 In the present study, we demonstrated that the generation of anti-GAG antibodies in chP3R99-immunized apoE −/− mice was related to the activation of an anti-idiotypic antibody cascade, first because IgG antibodies from IM (Ab3) reacted specifically with ch1E10 Ab2 mAb, and second because the reactivity against CS of the Ab3 antibodies was partially inhibited by preincubation of the sera with the Ab2 mAb.
Although further experiments are required to elucidate the mechanisms by which chP3R99 mAb immunization prevents atherosclerosis in apoE −/− fed an atherogenic diet, it is likely that the generation of anti-GAG antibodies during immunization interferes with the retention of lipoproteins and their further modification, as shown in studies in which IgGs from chP3R99-IM were capable to inhibit CS-dependent LDL oxidation in vitro, in addition to reducing the retention and oxidation of LDL in the arterial wall of apoE −/− mice fed with chow diet. These observations suggest that the anti-GAG antibodies generated by chP3R99 immunization may interfere with the subendothelial retention of LDL via direct binding to GAGs, which is the initiating event in atherosclerosis. 5, 39 Immunoglobulin transfer experiments may provide direct evidence for the atheroprotective capacity of the anti-GAG antibodies generated by chP3R99 immunization.
In addition to direct LDL-PG binding within the arterial wall, accumulating evidence shows the presence of indirect LDL binding through bridging and accessory molecules that promote retention, such as lipoprotein lipase and secretory sphingomyelinase. 34, 35 At least in vitro, neither chP3R99 mAb nor serum antibodies from IM were found to inhibit the binding of LDL mediated by these enzymes to atherosclerotic apoE −/− mouse aortas. Yet, additional studies will be necessary to assess whether chP3R99 immunization may have atheroprotective effect at later stages of atherosclerosis development because of the fact that extracellular matrix remodeling also involve other changes, such as the presence of PGs with elongated GAG chains that may promote LDL retention, 34, 40 along with the use of atherosclerotic mouse models that allow long-term study of aortic lesion development. 41 However, it is well-known that syndecan-1, a heparan sulfate PG, is a key molecular mediator for the hepatic clearance of atherogenic remnant lipoproteins from the circulation. [42] [43] [44] Therefore, an important limitation for the use of GAG-based antiatherogenic therapies is the potential interference with this physiological interaction. Considering the reactivity of chP3R99 mAb 26 and that of the antibodies induced by chP3R99 immunization with heparin, we evaluated their possible interference with VLDL binding to Huh7 human hepatoma cells, which express syndecan-1 on their plasma membrane. 45 Our results show that neither chP3R99 mAb nor the sera or IgG antibodies from IM inhibited the binding of the lipoproteins to the hepatic cells. Nevertheless, further toxicological studies should be performed to address the potential risks associated with the generation of antibodies against self-antigens such as PGs that are involved in many physiological processes. 46 In conclusion, our results provide evidence to support active immunization with immunogenic antibodies that strongly recognize GAGs as a novel therapeutic strategy to prevent atherosclerosis lesion development. The atheroprotective effect likely involves the induction of anti-anti-idiotypic antibodies capable of blocking the interaction between intimal PGs and LDL, thereby inhibiting LDL retention into the artery wall.
